Home / Business and Economy / Roche's Vabysmo Recovery Lags; Growth Relies on New Drug
Roche's Vabysmo Recovery Lags; Growth Relies on New Drug
23 Jul
Summary
- Roche's Q2 revenue reached 15.6 billion Swiss francs.
- The eye drug Vabysmo showed a slower recovery than anticipated.
- Investors are looking to a new key drug for future growth.
Roche Holding AG announced its second-quarter financial results on Thursday, revealing that revenue reached 15.6 billion Swiss francs ($19.2 billion). A key factor influencing these results was the performance of the eye drug Vabysmo. The drug's recovery has been slower than analysts had projected. This slower-than-expected uptake has led to increased investor focus on the company's pipeline.
Looking ahead, Roche is relying on a new, significant drug to become the primary engine for its future growth. This strategic pivot underscores the company's efforts to navigate market dynamics and secure sustained profitability in the evolving pharmaceutical landscape.
